Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.
Oncolytics Biotech Stock Performance
The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The business has a 50 day moving average price of C$14.90 and a 200 day moving average price of C$14.90. The stock has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
